Celularity Inc.

NASDAQ:CELU

Biotechnology

Healthcare
$1.83 +138.53%

+$1.22 today

Market cap
$52.97M
Beta
0.54
P/E (TTM)
-0.6
EPS (TTM)
-$3.58
52W Low $0.56High $4.00

Volume 0.00M

Average 0.13M

CELU Cost of Revenue

Direct costs of producing the goods and services sold, such as materials, manufacturing, and service delivery.

Celularity Inc.NASDAQ: CELU

Cost of Revenue · Q4 FY2025 · quarter ended Dec 2025

Cost of revenue turns negative

Q4 FY2025 cost of revenue was -$4.45M, compared with $7.34M a year earlier. Trailing-twelve-month cost of revenue was $6.36M. Over 3 fiscal years it compounded at -31.4% a year.

Context

  • Cost of revenue amounted to 24.0% of revenue in FY2025, down 3.7 pp from a year earlier.
  • Cost of revenue increased in 0 of the last 3 fiscal years.
  • FY2025 was the lowest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly cost of revenue holds near -$4.45M or moves back toward the trailing-twelve-month quarterly average of $1.59M.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterDec 2025
-$4.45M-320.6% QoQ
Last fiscal yearDec 2025
$6.36M-57.6% YoY
LTMDec 2025
$6.36M-57.6% YoY
Cost of Revenue past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter-160.6%——
1 year-57.6%——
3-year CAGR-31.4%——
5-year CAGR——
10-year CAGR——

Cost of Revenue history

USD · from the income statement

Latest · FY2025
6.36M USD
Year-over-year change
-57.6%
4-year CAGR
-9.9%

Cost of Revenue vs competitors

How CELU compares with its peers on the latest reported figures

  • CELU's LTM Dec 2025 cost of revenue of $6.36M is the highest of the 4 companies compared; the peer median is $0.
  • Its year-over-year change of -57.6% is the highest of 2, against a peer median of -197.3%.
  • Cost of revenue amounts to 24.0% of revenue for CELU, versus a peer median of 1.1%.
CELU Competitors Peer median
Cost of Revenue for CELU and competitors
Company Period LTM YoY 3-year CAGR% of revenue
CELUCelularity Inc.LTM Dec 2025$6.36M -57.6%-31.4%24.0%
PYPDPolyPid Ltd.LTM Mar 2026$0 ———
ANVSAnnovis Bio, Inc.LTM Mar 2026$0 ———
ATNMActinium Pharmaceuticals, Inc.LTM Jun 2026-$395K -197.3%—1.1%
Peer median (excluding CELU) $0-197.3%—1.1%

Competitors are the stored peer set for CELU. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue21.34M17.98M22.77M54.22M26.55M
Cost of Revenue9.65M19.67M16.02M14.99M6.36M
Gross Profit11.68M(1.69M)6.76M39.23M20.19M
Gross Margin54.8%-9.4%29.7%72.4%76.0%
Research & Development88.35M78.36M30.47M17.39M15.03M
Selling, General & Admin71.34M66.02M50.58M58.64M51.27M
Operating Expenses120.74M23.91M199.04M77.59M81.5M
Depreciation & Amortization8.82M9.44M9.32M7.92M7.3M
EBITDA(88.11M)(138.83M)(183.95M)(43.71M)(77.66M)
EBITDA Margin-413.0%-772.4%-807.8%-80.6%-292.5%
Operating Income(109.06M)(25.6M)(192.29M)(38.36M)(61.31M)
Operating Margin-511.2%-142.4%-844.4%-70.7%-230.9%
Interest Income332K365K320K331K262K
Interest Expense3.17M03.02M6.26M6.75M
Other Income / Expenses8.96M39.81M(4M)(19.53M)(30.41M)
Income Before Tax(100.1M)14.21M(196.29M)(57.89M)(91.71M)
Pre-Tax Margin-469.2%79.0%-862.0%-106.8%-345.4%
Income Tax Expense20K13K10K03K
Net Income(100.12M)14.19M(196.3M)(57.89M)(91.8M)
Net Margin-469.3%79.0%-862.0%-106.8%-345.8%
EPS (Basic)(7.87)1.01(11.02)(2.64)(3.59)
EPS (Diluted)(7.87)0.95(11.02)(2.64)(3.59)
Weighted Avg Shares12.73M13.99M17.81M21.89M25.6M
Weighted Avg Shares (Diluted)12.73M14.98M17.81M21.89M25.6M

Celularity Inc.

NASDAQ:CELU

Intrinsic Alpha fair value

Locked

Current Price

$1.83

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.